TSO3 appointed Bradley J. Catalone as its chief science officer. Catalone has extensive knowledge of medical devices and the sterilization industry. Previously, he served in leading roles at Olympus Corporation of the Americas, including as director of research. Most recently, he was vice president of laboratory services at Alcami Corporation with responsibility for drug development and analytical testing services.
Saranas appointed Philippe Généreux as its chief medical officer. Généreux is co-director of the structural heart disease program at Morristown Medical Center. Previously, Généreux was an interventional cardiologist at the Columbia Medical Center and the director of the angiographic core laboratory at the Cardiovascular Research Foundation. Saranas has developed a technology for early detection of bleeding complications associated with vascular access procedures.
OSF Ventures named Garrett Vygantas as managing director. Vygantas has two decades of healthcare experience as a physician, investor and entrepreneur. He has worked in biopharmaceuticals, medical technology and diagnostics. He was the founding CEO of NewBridge Pharmaceuticals and was also an entrepreneur-in-residence and investment director at a leading life science venture capital firm. Most recently, he led healthcare investments at Jump Capital.